JULIA VEGA: Open Payments
NPI 1992180517 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,384 in 66 payments from 21 companies in 2025. Trend: 2023 $1,459 · 2024 $2,062 · 2025 $1,384
Food & beverage: $1,336Education: $48
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 18 | $376 |
| Janssen Biotech, Inc. | 6 | $159 |
| GENZYME CORPORATION | 5 | $143 |
| AstraZeneca Pharmaceuticals LP | 3 | $80 |
| Gilead Sciences, Inc. | 3 | $66 |
| Celgene Corporation | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| ABBVIE INC. | 2 | $50 |
| Exelixis Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: IBRANCE, SARCLISA, Padcev, Trodelvy, TALVEY, REBLOZYL, DARZALEX, VENCLEXTA.
Industry payments across GA — which companies pay providers there.
